Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Katherine Ververis,1 Alison Hiong,1 Tom C Karagiannis,1,* Paul V Licciardi2,*1Epigenomic Medicine, Alfred Medical Research and Education Precinct, 2Allergy and Immune Disorders, Murdoch Childrens Research Institute, Melbourne, VIC, Australia*These authors contributed equally to this workAbstract: Hi...
Guardado en:
Autores principales: | Ververis K, Hiong A, Karagiannis TC, Licciardi PV |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/59ef244e4cd64ca2bf96ff421a175c18 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Madhumanti Barman, et al.
Publicado: (2021) -
Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Iason Psilopatis, et al.
Publicado: (2021) -
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment
por: Alp E, et al.
Publicado: (2019) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016) -
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
por: Jay H. Kalin, et al.
Publicado: (2018)